Combined transepicardial and transseptal implantation of autologous CD 133+ bone marrow cells during bypass grafting improves cardiac function in patients with low ejection fraction.
Tri Wisesa SoetisnaRenan SukmawanBudhi SetiantoMuchtaruddin MansyurTri Wahyu MurniErlin ListiyaningsihAnwar SantosoPublished in: Journal of cardiac surgery (2020)
Combined transepicardial and transseptal autologous CD133+ BMC implantation during bypass grafting improved cardiac function in low EF coronary artery disease patients.
Keyphrases
- ejection fraction
- bone marrow
- aortic stenosis
- coronary artery disease
- end stage renal disease
- induced apoptosis
- mesenchymal stem cells
- newly diagnosed
- chronic kidney disease
- cell therapy
- cell cycle arrest
- heart failure
- type diabetes
- cardiovascular events
- percutaneous coronary intervention
- peritoneal dialysis
- stem cells
- acute coronary syndrome
- nk cells
- patient reported outcomes
- cell death
- aortic valve